Conatus Raises $20M for Hepatitis C Studies

11:26 EST 14 Feb 2011 |

San Diego’s Conatus Pharmaceuticals, which specializes in developing drugs for liver disease and cancers, said it closed on a $20 million block of equity funding, which was led by a new investor, AgeChem Venture Fund of Montreal. Existing investors Aberdare Ventures, Advent Venture Partners, Bay City Capital, Gilde Healthcare Partners, and the Roche Venture Fund [...]

Original Article: Conatus Raises $20M for Hepatitis C Studies


More From BioPortfolio on "Conatus Raises $20M for Hepatitis C Studies"

Quick Search


Relevant Topics

Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...